No significant strengths identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| MNKDMannKind Corporation | 1.73B | 5.64 | 58.02 | 43.5% | 9.32% | 1.89% | ||
| CORTCorcept Therapeutics Incorporated | 3.82B | 36.35 | 29.55 | 39.94% | 14.19% | 16.65% | 5.12% | 0.01 |
| GUTSFractyl Health, Inc. Common Stock | 308.28M | 2.01 | -1.24 | -22.5% | -40732.33% | -241.68% | 2.20 | |
| LXRXLexicon Pharmaceuticals, Inc. | 436.08M | 1.20 | -1.90 | 24.81% | -96.77% | -57.07% | 0.74 | |
| RZLTRezolute, Inc. | 229.96M | 2.48 | -2.53 | -52.45% | 0.01 | |||
| MISTMilestone Pharmaceuticals Inc. | 164.38M | 1.93 | -2.88 | -100% | -282.97% | 4.17 | ||
| ALTAltimmune, Inc. | 418.41M | 4.01 | -2.99 | -95.31% | -4195.75% | -45.21% | 0.01 | |
| BIOABioAge Labs, Inc. | 741.84M | 20.69 | -3.12 | -12.81% | -27.32% | 0.03 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 15M | 5M | 1M | 0 |
| Revenue Growth % | - | - | - | - | - | -0.67% | -0.8% | -1% |
| Cost of Goods Sold | 8K | 10K | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | -8K | -10K | 0 | 0 | 15M | 5M | 1M | 0 |
| Gross Margin % | - | - | - | - | 1% | 1% | 1% | - |
| Gross Profit Growth % | - | -0.25% | 1% | - | - | -0.67% | -0.8% | -1% |
| Operating Expenses | 8.27M | 23.82M | 57.88M | 50.71M | 58.07M | 64.64M | 62.1M | 42.1M |
| OpEx % of Revenue | - | - | - | - | 3.87% | 12.93% | 62.1% | - |
| Selling, General & Admin | 2.63M | 6.97M | 15.62M | 15.9M | 19.4M | 24.81M | 31.05M | 27.75M |
| SG&A % of Revenue | - | - | - | - | 1.29% | 4.96% | 31.05% | - |
| Research & Development | 5.64M | 16.85M | 42.38M | 34.86M | 38.67M | 39.83M | 31.05M | 14.36M |
| R&D % of Revenue | - | - | - | - | 2.58% | 7.97% | 31.05% | - |
| Other Operating Expenses | 0 | 0 | -115K | -55K | 0 | 0 | 0 | 0 |
| Operating Income | -8.27M | -23.82M | -57.88M | -50.71M | -43.07M | -59.64M | -61.1M | -42.1M |
| Operating Margin % | - | - | - | - | -2.87% | -11.93% | -61.1% | - |
| Operating Income Growth % | - | -1.88% | -1.43% | 0.12% | 0.15% | -0.38% | -0.02% | 0.31% |
| EBITDA | -8.26M | -23.81M | -57.84M | -50.61M | -42.98M | -59.55M | -61.01M | -42M |
| EBITDA Margin % | - | - | - | - | -2.87% | -11.91% | -61.01% | - |
| EBITDA Growth % | - | -1.88% | -1.43% | 0.12% | 0.15% | -0.39% | -0.02% | 0.31% |
| D&A (Non-Cash Add-back) | 8K | 10K | 38K | 97K | 93K | 89K | 92K | 105K |
| EBIT | -8.27M | -23.37M | -57.88M | -50.71M | -43.07M | -58.39M | -57.13M | -37.94M |
| Net Interest Income | 0 | 0 | 0 | 0 | 220K | 1.25M | 1.41M | 7.75M |
| Interest Income | 186K | 711K | 2.6M | 726K | 220K | 1.25M | 3.97M | 4.16M |
| Interest Expense | 0 | 0 | 2.6M | 726K | 0 | 0 | 2.55M | -3.58M |
| Other Income/Expense | 186K | 711K | 2.6M | 726K | 220K | 1.25M | 1.41M | 583K |
| Pretax Income | -8.08M | -23.11M | 55.28M | -49.98M | -42.85M | -58.39M | -59.69M | -41.52M |
| Pretax Margin % | - | - | - | - | -2.86% | -11.68% | -59.69% | - |
| Income Tax | 4K | 74K | 56K | -17K | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | -1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -8.09M | -23.18M | -55.23M | -49.97M | -42.85M | -58.39M | -59.69M | -41.52M |
| Net Margin % | - | - | - | - | -2.86% | -11.68% | -59.69% | - |
| Net Income Growth % | - | -1.87% | -1.38% | 0.1% | 0.14% | -0.36% | -0.02% | 0.3% |
| Net Income (Continuing) | -8.09M | -23.18M | -55.23M | -49.97M | -42.85M | -58.39M | -59.69M | -41.52M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.34 | -0.98 | -3.50 | -1.70 | -1.02 | -1.35 | -1.39 | -0.67 |
| EPS Growth % | - | -1.88% | -2.57% | 0.51% | 0.4% | -0.32% | -0.03% | 0.52% |
| EPS (Basic) | -0.34 | -0.98 | -3.50 | -1.70 | -1.02 | -1.35 | -1.39 | -0.67 |
| Diluted Shares Outstanding | 23.65M | 23.65M | 15.78M | 29.34M | 41.83M | 42.45M | 42.96M | 62.21M |
| Basic Shares Outstanding | 23.65M | 23.65M | 15.78M | 29.34M | 41.83M | 42.45M | 42.96M | 62.21M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 27.55M | 88.05M | 122.5M | 148.69M | 118.92M | 71.8M | 73.03M | 73.93M |
| Cash & Short-Term Investments | 26.91M | 85.98M | 119.82M | 142.31M | 114.14M | 64.58M | 66M | 69.69M |
| Cash Only | 10.88M | 85.95M | 119.82M | 72.31M | 114.14M | 7.64M | 13.76M | 25.31M |
| Short-Term Investments | 16.03M | 29K | 0 | 70M | 0 | 56.95M | 52.24M | 44.38M |
| Accounts Receivable | 543K | 677K | 0 | 0 | 483K | 1.21M | 3.85M | 2.39M |
| Days Sales Outstanding | - | - | - | - | 11.75 | 88.55 | 1.41K | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 836K | 948K | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 35K | 30K | 929K | 1.29M | 926K | 2.68M | 2.19M | 1.57M |
| Property, Plant & Equipment | 35K | 30K | 929K | 1.29M | 926K | 2.68M | 2.19M | 1.57M |
| Fixed Asset Turnover | - | - | - | - | 16.20x | 1.87x | 0.46x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 27.59M | 88.08M | 123.43M | 149.97M | 119.85M | 74.48M | 75.23M | 75.5M |
| Asset Turnover | - | - | - | - | 0.13x | 0.07x | 0.01x | - |
| Asset Growth % | - | 2.19% | 0.4% | 0.22% | -0.2% | -0.38% | 0.01% | 0% |
| Total Current Liabilities | 1.6M | 4.53M | 8.33M | 6.16M | 6.78M | 6.14M | 7.23M | 8.13M |
| Accounts Payable | 4K | 2.6M | 4.38M | 4.64M | 4.38M | 2.26M | 3.98M | 1.93M |
| Days Payables Outstanding | 182.5 | 95.01K | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 224K | 495K | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.11M | 56K | 0 | 0 | 709K | 808K | 1.99M | 0 |
| Current Ratio | 17.17x | 19.42x | 14.71x | 24.14x | 17.55x | 11.70x | 10.11x | 9.10x |
| Quick Ratio | 17.17x | 19.42x | 14.71x | 24.14x | 17.55x | 11.70x | 10.11x | 9.10x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 59.1M | 138.76M | 184K | 696K | 474K | 2M | 51.23M | 54.23M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 49.77M | 53.35M |
| Capital Lease Obligations | 0 | 0 | 184K | 696K | 474K | 2M | 1.46M | 874K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 59.1M | 138.76M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 60.71M | 143.29M | 8.51M | 6.86M | 7.25M | 8.13M | 58.45M | 62.35M |
| Total Debt | 0 | 0 | 514K | 941K | 698K | 2.49M | 51.77M | 54.8M |
| Net Debt | -10.88M | -85.95M | -119.3M | -71.37M | -113.44M | -5.14M | 38.02M | 29.48M |
| Debt / Equity | - | - | 0.00x | 0.01x | 0.01x | 0.04x | 3.09x | 4.17x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | -22.30x | -69.85x | - | - | -23.92x | - |
| Total Equity | -33.12M | -55.21M | 114.92M | 143.12M | 112.6M | 66.35M | 16.77M | 13.15M |
| Equity Growth % | - | -0.67% | 3.08% | 0.25% | -0.21% | -0.41% | -0.75% | -0.22% |
| Book Value per Share | -1.40 | -2.33 | 7.28 | 4.88 | 2.69 | 1.56 | 0.39 | 0.21 |
| Total Shareholders' Equity | -33.12M | -55.21M | 114.92M | 143.12M | 112.6M | 66.35M | 16.77M | 13.15M |
| Common Stock | 1.23M | 2.04M | 226.25M | 251.68M | 251.9M | 273.9M | 260.5M | 288.05M |
| Retained Earnings | -35.09M | -58.27M | -113.5M | -163.47M | -206.32M | -266.34M | -326.03M | -367.55M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.63M | -1.63M | -1.63M | 46.37M | 51.31M | 34.35M | 48.46M | 53.08M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -8.05M | -21.05M | -51.15M | -50.73M | -33.22M | -52.47M | -46.42M | -28.85M |
| Operating CF Margin % | - | - | - | - | -2.21% | -10.49% | -46.42% | - |
| Operating CF Growth % | - | -1.61% | -1.43% | 0.01% | 0.35% | -0.58% | 0.12% | 0.38% |
| Net Income | -8.09M | -23.18M | -55.23M | -49.97M | -42.85M | -58.39M | -59.69M | -41.52M |
| Depreciation & Amortization | 8K | 10K | 38K | 97K | 93K | 89K | 92K | 105K |
| Stock-Based Compensation | 190K | 633K | 1.19M | 4.95M | 7.28M | 9.05M | 9.53M | 5.78M |
| Deferred Taxes | 0 | 0 | -1.63M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 59K | 787K | 1.63M | 0 | 0 | 44K | 2.39M | 3.13M |
| Working Capital Changes | -164K | 1.5M | 2.85M | -5.81M | 2.26M | -3.26M | 1.24M | 3.66M |
| Change in Receivables | 147K | -134K | -169K | -112K | 465K | -730K | -2.64M | 1.46M |
| Change in Inventory | 0 | 0 | 169K | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -222K | 2.88M | 3.52M | -2.08M | 0 | 0 | 0 | 0 |
| Cash from Investing | -16.02M | 16M | -384K | -70M | 70M | -57.12M | 4.76M | 8.28M |
| Capital Expenditures | -36K | -5K | -413K | 0 | 0 | -272K | -112K | -33K |
| CapEx % of Revenue | - | - | - | - | - | 0.05% | 0.11% | - |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | -15.99M | 16M | -35.41M | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 30.72M | 80.11M | 85.41M | 73.22M | 5.05M | 3.09M | 47.79M | 32.12M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | -278K | 461K | 44K | 48.31M | 5.05M | 458K | -2.21M | 4.86M |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | -8.09M | -21.05M | -51.56M | -50.73M | -33.22M | -52.74M | -46.54M | -28.88M |
| FCF Margin % | - | - | - | - | -2.21% | -10.55% | -46.54% | - |
| FCF Growth % | - | -1.6% | -1.45% | 0.02% | 0.35% | -0.59% | 0.12% | 0.38% |
| FCF per Share | -0.34 | -0.89 | -3.27 | -1.73 | -0.79 | -1.24 | -1.08 | -0.46 |
| FCF Conversion (FCF/Net Income) | 1.00x | 0.91x | 0.93x | 1.02x | 0.78x | 0.90x | 0.78x | 0.69x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -185% | -38.73% | -33.52% | -65.26% | -143.61% | -277.55% |
| Return on Invested Capital (ROIC) | - | - | - | -112.92% | -91.12% | -148.22% | -79.01% | -64.83% |
| Gross Margin | - | - | - | - | 100% | 100% | 100% | - |
| Net Margin | - | - | - | - | -285.69% | -1167.76% | -5968.5% | - |
| Debt / Equity | - | - | 0.00x | 0.01x | 0.01x | 0.04x | 3.09x | 4.17x |
| Interest Coverage | - | - | -22.30x | -69.85x | - | - | -23.92x | - |
| FCF Conversion | 1.00x | 0.91x | 0.93x | 1.02x | 0.78x | 0.90x | 0.78x | 0.69x |
| Revenue Growth | - | - | - | - | - | -66.67% | -80% | -100% |
Milestone Pharmaceuticals Inc. (MIST) saw revenue decline by 100.0% over the past year.
Milestone Pharmaceuticals Inc. (MIST) reported a net loss of $58.0M for fiscal year 2024.
Milestone Pharmaceuticals Inc. (MIST) has a return on equity (ROE) of -277.6%. Negative ROE indicates the company is unprofitable.
Milestone Pharmaceuticals Inc. (MIST) had negative free cash flow of $43.2M in fiscal year 2024, likely due to heavy capital investments.